Abstract Number: 0677 • ACR Convergence 2024
Patterns of Raynaud’s Phenomenon Management in Patients with Systemic Sclerosis: A Real-World Data from Community-Based Practices in the United States
Background/Purpose: Raynaud’s phenomenon (RP) and the complex vasculopathy of systemic sclerosis (SSc) can lead to chronic digital ischemia, ulcerations, and necrosis with significant pain and…Abstract Number: 0679 • ACR Convergence 2024
Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study
Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene. Despite…Abstract Number: 0703 • ACR Convergence 2024
Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Background/Purpose: While 95% of Systemic Sclerosis (SSc) patients have Raynaud’s phenomenon(RP) and many patients rate it as the most bothersome and severe symptom of their…Abstract Number: 1586 • ACR Convergence 2024
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Background/Purpose: Telangiectasia are permanently dilated dermal postcapillary venules and are the 2nd most common manifestation (~80%) of systemic sclerosis (SSc) after Raynaud’s phenomenon (RP). The…Abstract Number: 1956 • ACR Convergence 2024
Artificial Intelligence Enhanced Analysis of Nailfold Capillaries by Dermatoscopy in Rheumatology Centers
Background/Purpose: The use of dermatoscopes in rheumatology has been established for several years. However, the application of artificial intelligence for the detection of abnormalities in…Abstract Number: 2069 • ACR Convergence 2024
Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort
Background/Purpose: Idiopathic inflammatory myopathy (IIM) carries an elevated cancer risk. The International Myositis Assessment and Clinical Studies Group (IMACS) has issued evidence-based guidelines for cancer…Abstract Number: 2442 • ACR Convergence 2024
Clustering Algorithm as an Exploratory Analysis of Different Clinical Phenotypes in Systemic Sclerosis. Data from the PRECISESADS Study
Background/Purpose: Systemic sclerosis is a systemic autoimmune disease with multiorgan involvement. Its pathophysiology is based on three pillars: vasculopathy, fibrosis, and autoimmunity. Despite advances in…Abstract Number: 0625 • ACR Convergence 2023
Use of Heated Gloves for Raynaud’s Phenomenon in Systemic Sclerosis
Background/Purpose: RP and its ischaemic complications are a major cause of morbidity in SSc. Non-pharmacological measures to minimise cold exposure can play a vital role…Abstract Number: 1474 • ACR Convergence 2023
Associations and Outcomes of Critical Peripheral Ischemia in Systemic Lupus Erythematosus (SLE): Data from Indian SLE Inception Cohort for Research (INSPIRE)
Background/Purpose: Among the cutaneous manifestations of SLE, critical peripheral ischemia (CPI) including digital infarcts and gangrene are considered rare, gangrene occurring only in about 0.2%…Abstract Number: 1518 • ACR Convergence 2023
Efficacy and Safety of Prostaglandins Analogues in Systemic Sclerosis-associated Raynaud’s Phenomenon. a Systematic Review and Meta-Analysis
Background/Purpose: Raynaud's phenomenon (RP) is a vasculopathic manifestation of Systemic Sclerosis (SSc) that can lead to digital ulceration, gangrene, autoamputation, and hand disability. Prostaglandin analogs…Abstract Number: 1520 • ACR Convergence 2023
Identifying Core Domains for Clinical Trials in Systemic Sclerosis-Associated Raynaud’s Phenomenon and Digital Ulcers Using the Delphi Consensus Method
Background/Purpose: The OMERACT Scleroderma Vascular Disease Working Group sought to identify essential core outcome domains for inclusion in clinical trials focusing on Raynaud's phenomenon (RP)…Abstract Number: 1527 • ACR Convergence 2023
Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients
Background/Purpose: So far few studies explored ultrasound (US) as a tool to assess vascular subcutaneous involvement in patients affected by systemic sclerosis (SSc). We aim…Abstract Number: 1875 • ACR Convergence 2023
Inter and Intra-observer Reliability of Assessment for Nailfold Capillary Abnormalities in Rheumatic Patients with Raynaud’s Phenomenon
Background/Purpose: To investigate the consistency of rheumatologists' assessment of nailfold capillaroscopy images of patients with Raynaud's phenomenon (RP). Methods: Nailfold video capillaroscopy(NVC), with a 200x…Abstract Number: 074 • 2023 Pediatric Rheumatology Symposium
Clinical Characteristics of Juvenile Systemic Sclerosis in Korea: A 30-year Single Center Study
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare autoimmune, chronic, multisystem, connective tissue disease characterized by progressive tissue fibrosis of the skin and internal organs.…Abstract Number: 2036 • ACR Convergence 2022
Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease, and Raynaud's Phenomenon (RP) is an extraglandular manifestation that can evolve into a systemic sclerosis-overlap syndrome.…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »
